Clinical Trial · NCT01985971

F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer

Overview

To estimate the presence of hypoxia in individual lesions after radiotherapy in patients with brain metastases from breast cancer as identified by F18 EF5 PET/CT imaging.

Sponsor

Abramson Cancer Center of the University of Pennsylvania

Phase

N/A

Contacts

Lilie Lin, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01985971

Eligibility

Inclusion

Ability to undergo brain MR and PET imaging
The effects of EF5 on the developing human fetus are unknown. For this reason, women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation (1 month). Should a woman become pregnant pr suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women of childbearing potential will have a urine pregnancy test the day of the F18 -EF5 PET scan prior to the F18 -EF5 injection.
Subjects who are allergic to gadolinium will have MRI scans without gadolinium contrast.
Subjects with measurable brain metastases of at least 1 cm in any plane based on anatomic imaging.
Subjects with prior resection of brain metastases with progressions on brain MRI.
Histologic confirmation of breast cancer.
Study subjects must have normal organ and marrow function as defined below:WBC \>2,000/mmᶟ, platelets \>90,000/mmᶟ, total bilirubin \<2.0 mg/dl, creatinine \<2.0 mg/dl.
ECOG Performance Status ≤ 2.

Exclusion

Subject has any other condition or personal circumstance that, in the judgement of the investigator, might interfere with the collection of complete good quality data.
History of allergic reactions attributed to Flagyl (metronidazole), which has a chemical structure similar to EF5.
Patients with moderate to severe renal failure, defined as estimated GFR less than 30 ml/Lmin 1.73m²
Patients with prior whole brain radiotherapy.
Pregnant women are excluded because EF5 has an unknown risk for adverse events in fetuses and nursing infants secondary the administration of EF5 to the mother. Breastfeeding should be discontinued if EF5 is administered to the mother.